- PIPELINE -

OUR INTERNAL DEVELOPMENT PROGRAMS

Parallel to the support of client projects the Salzman Group pursues internal development programs that are strictly separated from the service activities by dedicated project managers.


R-107 for Chlorine Inhalation Lung Injury

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded Salzman Group with a $15.9 million contract for development of R-107, the first potential antidote to treat the life-threatening effects of chlorine inhalation, a potential terrorism threat. The contract is part of efforts by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) to develop medical products and procedures to protect health and save lives in a terrorist attack, including those using toxic industrial chemicals such as chlorine. The funding will support the advancement of R-107 in manufacturing, pharmacology, and toxicology. If non-clinical studies are successful, R-107 could begin clinical studies to establish safety in humans, and the contract could be extended up to a total of $84.9 million over seven years.

> read more

RvE1 (R-10001) for Crohn’s Disease (Quitsa Pharmaceuticals)

Quitsa Pharmaceuticals, a spin-out of Salzman Investments Ltd., is advancing an anti-inflammatory broad-spectrum bioactive lipid, R-10001, as a first-line agent for the prophylaxis of Crohn’s Disease (CD) refractory to biologic (Anti-TNF-α) treatment. This growing market segment constitutes a significant unmet medical need of < 200,000 US patients, thus meriting orphan drug designation. 

> read more

back to top